# Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria

> **NCT05287893** · PHASE1 · COMPLETED · sponsor: **Medicines for Malaria Venture** · enrollment: 10 (actual)

## Conditions studied

- Malaria,Falciparum
- Malaria
- Malaria Recrudescence
- Parasitemia
- Protozoan Infections
- Parasitic Disease

## Interventions

- **DRUG:** Pyronaridine
- **BIOLOGICAL:** P. falciparum IBSM infection

## Key facts

- **NCT ID:** NCT05287893
- **Lead sponsor:** Medicines for Malaria Venture
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-04
- **Primary completion:** 2022-09-26
- **Final completion:** 2022-09-26
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-04-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05287893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05287893, "Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05287893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*